Cardiol Therapeutics to Present at the 2018 Biotech Showcase in San Francisco
Toronto, Ontario, January 3rd, 2018 – Cardiol Therapeutics Inc. (“Cardiol” or the “Company”), a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure, is pleased to announce that it will be presenting at the 2018 Biotech Showcase in San Francisco.
Cardiol’s President and CEO, David Elsley, will present a corporate overview on Tuesday, January 9th, 2018 at 2 PM PST at the Hilton San Francisco Union Square in Yosemite A on the Ballroom Level.
Now in its tenth year, Biotech Showcase is a premier investor and partnering conference that consistently attracts institutional investors, private equity, venture capital, foundations, angels and family offices, senior executives from public and private biotech companies, buy- and sell-side analysts, and business development executives from pharma companies. It is one of the industry’s largest annual healthcare investor conferences with over USD 334 billion in capital represented by public and private investors attending.
About Cardiol Therapeutics
Cardiol Therapeutics is a nanotherapeutics company focused on the research and commercial development of proprietary drug formulations for the treatment of heart failure. Heart failure is a chronic condition that affects more than 26 million people globally. Over five million adults in the U.S. suffer from heart failure, and it remains a leading cause of death and hospitalization with associated healthcare costs exceeding $30 billion annually. People with heart failure experience shortness of breath, fatigue, rapid heart rate, edema, reduced exercise capacity and a marked reduction in quality of life. Approximately half of all heart failure patients have heart failure with preserved ejection fraction (HFpEF), which is often associated with diabetes, obesity, and high blood pressure and for which there have been no new therapies developed in over 20 years. Cardiol is developing CTX01, a proprietary nanoformulation of pharmaceutical cannabidiol for the treatment of HFpEF. Cannabidiol has been shown to attenuate cardiac dysfunction in experimental models of diabetic cardiomyopathy and to decrease oxidative stress, fibrosis, and inflammation in other models relevant to HFpEF. CTX01 is designed to optimize and maintain blood levels of cannabidiol and target the drug to areas of inflammation in the heart. Cardiol is also developing CTX02, a proprietary nanoformulation of methotrexate for the treatment of heart failure. Recent experimental data have shown that methotrexate improves cardiac function after acute myocardial infarction and has anti-fibrotic properties. For further information, please visit crdl.starnix.com.